Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis.
In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up DXA, with an interval of 19.2 +/- 7.1 months. Thirty-six patients were treated with bisphosphonates (alendronate=23 and risedronate=13). Median follow-up Bone Mineral Density in the bisphosphonate group was 3.7% greater at the lumbar spine (95%CI 1.9 to 5.7%, P<0.0005) and 2.4% greater at the femur (95%CI 0.8 to 3.9%, P<0.005) than the group not treated with bisphosphonates. Oral bisphosphonate therapy had a beneficial effect on BMD in adults with CF.
Cawood
T J
TJ
Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland. tomjcawood@eircom.net
McKenna
M J
MJ
Gallagher
C G
CG
Smith
D
D
Wen
Y C
YC
Gibney
J
J
Dodd
J D
JD
O'Shea
D
D
D000284:Administration, Oral; D000328:Adult; D015519:Bone Density / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003550:Cystic Fibrosis / Q000503:physiopathology*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies
D050071:Bone Density Conservation Agents; D004164:Diphosphonates